Geoffrey Schwertz

PhD Student

Location: HCI G-312
Phone: +41-44-63-22998
Geoffrey Schwertz


2007–2009: Higher National Diploma in Chemistry, Institute of Technology, Strasbourg, France
2009: Internship at Prestwick Chemical, Illkirch-Graffenstaden, France
2009–2013: BSc and “diplome d’ingénieur” in Chemistry, specialization in Organic Chemistry, ECPM Strasbourg, France
2011: Internship at Novartis NIBR, Basel, Switzerland
2012: Internship at Sanofi, Vitry-sur-Seine, France
2012–2013: MSc in Molecular and Supramolecular Chemistry at Strasbourg University, France
2013: Master Thesis with Prof. F. Colobert at Strasbourg University, CNRS, UMR7509, France
Since 2013: PhD student with Prof. F. Diederich at ETH Zürich, Switzerland

Development of a Novel Antimalarial Drug: Structure-Based Design and Synthesis of Inhibitors for Serine Hydroxymethyltransferase (SHMT)

Due to the development of resistance against antimalarials there is an urgent need for novel treatment for this disease. Lately a new target enzyme in Plasmodium falciparum has been discovered, the serine hydroxymethyltransferase (SHMT) (Nirmalan, N. et al. Molecular Microbiology 2002, 46, 179–190.). SHMT is an essential enzyme involved in the synthesis of DNA precursors by catalysing the transfer of a C1-unit within parasite’s cells. The aim of the project is to develop an inhibitor of the active site of PfSHMT in order to stop parasite’s cells proliferation and eradicate the disease.

Structure of SHMT

Last update: November 2013